Cholesterol drug Livalo launched

INDIANAPOLIS A new cholesterol drug made by Eli Lilly and Kowa Pharmaceuticals America has become available, the two drug makers said Monday.

Livalo (pitavastatin), which received Food and Drug Administration approval in August 2009, is available in doses of 1 mg, 2 mg and 4 mg for the treatment of primary hyperlipidemia and mixed dyslipidemia. Clinical trials have shown Livalo to reduce “bad” LDL cholesterol by 39% at the 2 mg dose and by 45% at the 4 mg dose, the companies said, saying that the drug may be an attractive option for patients taking multiple medications due to its relatively low risk of certain drug interactions.

“Since many patients treated for elevated cholesterol may be on multiple medications, it is important that physicians and pharmacists caring for these patients understand how treatment with a cholesterol medication, such as a statin, may potentially interact with the other drugs the patient may be taking,” University of Chicago Pritzker School of Medicine director for preventive cardiology Michael Davidson stated on behalf of the two drug makers.

Login or Register to post a comment.